Back to top
more

Jazz Pharmaceuticals (JAZZ)

(Delayed Data from NSDQ)

$110.45 USD

110.45
389,055

+0.42 (0.38%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $110.46 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

by Zacks Equity Research

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

Zoetis (ZTS) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Jazz Starts CAR T-cell Linked Neurotoxicity Study Enrollment

by Zacks Equity Research

Jazz (JAZZ) enrolls first patient in a mid-stage study to evaluate defibrotide in prevention of neurotoxicity in relapsed/refractory DLBCL patients receiving CAR T-cell therapy.

5 High Earnings Yield Stocks to Buy for a Rewarding Portfolio

by Zacks Equity Research

Here are five stocks with high earnings yield that can be picked for a solid portfolio.

Jazz Pharmaceuticals Enters Oversold Territory

by Zacks Equity Research

Jazz Pharmaceuticals plc (JAZZ) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

by Zacks Equity Research

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

Is Jazz Pharmaceuticals (JAZZ) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

JAZZ vs. CTLT: Which Stock Is the Better Value Option?

by Zacks Equity Research

JAZZ vs. CTLT: Which Stock Is the Better Value Option?

Should Value Investors Buy Jazz Pharmaceuticals (JAZZ) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Jazz Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Jazz Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

Jazz (JAZZ) Down 7.4% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is Jazz Pharmaceuticals (JAZZ) a Profitable Value Stock?

by Zacks Equity Research

Jazz Pharmaceuticals (JAZZ) stock may be a good choice for value-oriented investors right now from multiple angles.

Jazz (JAZZ) Acquires Cavion, Adds Movement Disorder Candidate

by Zacks Equity Research

Jazz (JAZZ) acquires privately-held Cavion for a total consideration of $312.5 million including an upfront payment of $52.5 million and $260 million in potential clinical, regulatory and commercial milestones.

Jazz Pharma (JAZZ) Q2 Earnings and Sales Beat Estimates

by Zacks Equity Research

Jazz Pharmaceuticals (JAZZ) reports encouraging second-quarter 2019 earnings and revenues and raises its sales guidance for 2019.

Jazz Pharmaceuticals (JAZZ) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Jazz (JAZZ) delivered earnings and revenue surprises of 13.45% and 5.08%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

What's in the Cards for Bausch Health (BHC) in Q2 Earnings?

by Zacks Equity Research

Investors are looking forward to the performance of Salix and Bausch + Lomb, and other pipeline updates, when Bausch (BHC) reports Q2 results on Aug 6.

Is a Beat in the Cards for Regeneron (REGN) Q2 Earnings?

by Zacks Equity Research

Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports second-quarter 2019 results.

Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Jazz (JAZZ) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Jazz (JAZZ) Acquires Early-Stage Precision Oncology Asset

by Zacks Equity Research

Jazz (JAZZ) acquired Redx Pharma's early stage pan-RAF inhibitor program for developing potential treatment for cancer with RAF and RAS mutations.

Sanghamitra Saha headshot

ETF & Stock Winners of Longest US Economic Expansion

by Sanghamitra Saha

The U.S. economy has stepped into the 11th year of the expansion, exhibiting the longest expansion in history. These winning ETFs and stocks will rally further.

JAZZ or PCRX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

JAZZ vs. PCRX: Which Stock Is the Better Value Option?

Jazz's (JAZZ) New Sleep Drug Sunosi Gets Schedule IV Status

by Zacks Equity Research

Jazz Pharmaceuticals' (JAZZ) recently approved sleep drug, Sunosi, receives schedule IV designation under controlled substance list from the Drug Enforcement Agency.

Should Value Investors Buy Jazz Pharmaceuticals (JAZZ) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Why Is Jazz (JAZZ) Down 7.3% Since Last Earnings Report?

by Zacks Equity Research

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.